{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:07:11Z","timestamp":1790723231219,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose of Review<\/jats:title>\n            <jats:p>This article explores the intricate relationship between androgens, androgen receptors, and the central nervous system. We examine the role of physiologically derived androgens and androgenic supplements in neurodevelopment and neuroplasticity and delve into the involvement of androgen pathways in the pathogenesis of various neurological disorders.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent Findings<\/jats:title>\n            <jats:p>This review highlights the increasing recognition of testosterone and androgen signaling in various neurological conditions, with evidence of both protective and harmful effects depending on dosage and context. Although limited to experimental use, testosterone replacement therapy (TRT) may serve potential benefits in the management of multiple sclerosis, epilepsy, headache, Duchenne muscular dystrophy, amyotrophic lateral sclerosis, and Parkinson disease. On the other hand, androgen-blocking treatments may help alter disease progression in spinal and bulbar muscular atrophy. Testosterone supplementation can have potential adverse events when used at a supratherapeutic level, and prenatal testosterone exposure is believed to contribute to the pathogenesis of neurodevelopmental disease. Additionally, androgen-blocking agents could increase the risk of neurodegenerative conditions, such as Parkinson disease and Alzheimer disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Despite the above findings, there is no established indication of TRT or androgen-blocking medication in neurological disorders. The body of evidence highlighting the involvement of androgens and androgen receptors (ARs) in pathogenesis of neurological diseases is growing. This includes ongoing research exploring the potential therapeutic targets involving the androgen signaling pathway for management of neurological disorders. Future placebo-controlled clinical trials are essential to determine the efficacy and safety of TRT or androgen-blocking therapies in managing neurological disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11910-025-01426-6","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T08:57:42Z","timestamp":1748941062000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Neurology of Androgens and Androgenic Supplements"],"prefix":"10.1007","volume":"25","author":[{"given":"Chetna","family":"Dengri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Mayberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Koriesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amre","family":"Nouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"1426_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-61733-9","volume":"14","author":"DA Dart","year":"2024","unstructured":"Dart DA, Bevan CL, Uysal-Onganer P. Jiang WG Analysis of androgen receptor expression and activity in the mouse brain. Sci Rep. 2024;14:1\u201320. https:\/\/doi.org\/10.1038\/s41598-024-61733-9.","journal-title":"Sci Rep"},{"key":"1426_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/joa.13407","volume":"239","author":"RL Coolen","year":"2021","unstructured":"Coolen RL, Cambier JC, Spantidea PI, van Asselt E, Blok BFM. Androgen receptors in areas of the spinal cord and brainstem: A study in adult male cats. J Anat. 2021;239:125. https:\/\/doi.org\/10.1111\/joa.13407.","journal-title":"J Anat"},{"key":"1426_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.mce.2017.08.001","volume":"465","author":"S Mhaouty-Kodja","year":"2018","unstructured":"Mhaouty-Kodja S. Role of the androgen receptor in the central nervous system. Mol Cell Endocrinol. 2018;465:103\u201312. https:\/\/doi.org\/10.1016\/j.mce.2017.08.001.","journal-title":"Mol Cell Endocrinol"},{"key":"1426_CR4","doi-asserted-by":"publisher","unstructured":"Nguyen TV. Developmental effects of androgens in the human brain. Journal of neuroendocrinology 2018;30(2). https:\/\/doi.org\/10.1111\/jne.12486.","DOI":"10.1111\/jne.12486"},{"key":"1426_CR5","doi-asserted-by":"publisher","first-page":"1371148","DOI":"10.3389\/fendo.2024.1371148","volume":"15","author":"Z Wang","year":"2024","unstructured":"Wang Z, Zhang B, Mu C, Qiao D, Chen H, Zhao Y, Cui H, Zhang R, Li S. Androgen levels in autism spectrum disorders: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2024;15:1371148. https:\/\/doi.org\/10.3389\/fendo.2024.1371148.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1426_CR6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.earlhumdev.2008.09.006","volume":"84","author":"M Hines","year":"2008","unstructured":"Hines M. Early androgen influences on human neural and behavioural development. Early Human Dev. 2008;84:805\u20137. https:\/\/doi.org\/10.1016\/j.earlhumdev.2008.09.006.","journal-title":"Early Human Dev"},{"key":"1426_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13293-020-00307-6","volume":"11","author":"KE Kight","year":"2020","unstructured":"Kight KE, McCarthy MM. Androgens and the developing hippocampus. Biol Sex Differ. 2020;11:30. https:\/\/doi.org\/10.1186\/s13293-020-00307-6.","journal-title":"Biol Sex Differ"},{"key":"1426_CR8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/aje\/kwaa219","volume":"190","author":"RS Rotem","year":"2021","unstructured":"Rotem RS, Nguyen VT, Chodick G, Davidovitch M, Shalev V, Hauser R, Coull BA, Bellavia A, Weisskopf MG. Associations of Maternal Androgen-Related Conditions With Risk of Autism Spectrum Disorder in Progeny and Mediation by Cardiovascular, Metabolic, and Fertility Factors. Am J Epidemiol. 2021;190:600\u201310. https:\/\/doi.org\/10.1093\/aje\/kwaa219.","journal-title":"Am J Epidemiol"},{"key":"1426_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-62817-2_1","volume":"1015","author":"R von Bernhardi","year":"2017","unstructured":"von Bernhardi R, Bernhardi LE. Eugen\u00edn J (2017) What Is Neural Plasticity? Adv Exp Med Biol. 2017;1015:1\u201315. https:\/\/doi.org\/10.1007\/978-3-319-62817-2_1.","journal-title":"Adv Exp Med Biol"},{"key":"1426_CR10","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1210\/en.2019-00114","volume":"160","author":"P Duarte-Guterman","year":"2019","unstructured":"Duarte-Guterman P, Lieblich SE, Wainwright SR, Chow C, Chaiton JA, Watson NV, Galea LAM. Androgens Enhance Adult Hippocampal Neurogenesis in Males but Not Females in an Age-Dependent Manner. Endocrinology. 2019;160:2128\u201336. https:\/\/doi.org\/10.1210\/en.2019-00114.","journal-title":"Endocrinology"},{"key":"1426_CR11","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.3892\/etm.2016.3470","volume":"12","author":"W Pan","year":"2016","unstructured":"Pan W, Han S, Kang L, Li S, Du J, Cui H. Effects of dihydrotestosterone on synaptic plasticity of the hippocampus in mild cognitive impairment male SAMP8 mice. Exp Ther Med. 2016;12:1455\u201363. https:\/\/doi.org\/10.3892\/etm.2016.3470.","journal-title":"Exp Ther Med"},{"key":"1426_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-021-04330-4","volume":"602","author":"I Kelava","year":"2022","unstructured":"Kelava I, Chiaradia I, Pellegrini L, Kalinka AT, Lancaster MA. Androgens increase excitatory neurogenic potential in human brain organoids. Nature. 2022;602:112\u20136. https:\/\/doi.org\/10.1038\/s41586-021-04330-4.","journal-title":"Nature"},{"key":"1426_CR13","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/MED.0000000000000675","volume":"28","author":"M Scarth","year":"2021","unstructured":"Scarth M, Bj\u00f8rnebekk A. Androgen abuse and the brain. Curr Opin Endocrinol Diabetes Obes. 2021;28:604. https:\/\/doi.org\/10.1097\/MED.0000000000000675.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1426_CR14","unstructured":"Endocrine Society. Testosterone Therapy for Hypogonadism Guideline Resources. Endocrine Society. [Internet]. Washington, DC: Endocrine Society; 2018 Mar 19 [cited 2025 May 5]. Available from: https:\/\/www.endocrine.org\/clinical-practice-guidelines\/testosterone-therapy"},{"key":"1426_CR15","unstructured":"Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. American Urological Association. [Internet]. 2018 Mar 19 [cited 2025 May 5]. Available from: https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/testosterone-deficiency-guideline"},{"key":"1426_CR16","doi-asserted-by":"publisher","first-page":"1422931","DOI":"10.3389\/fneur.2024.1422931","volume":"15","author":"C Dengri","year":"2024","unstructured":"Dengri C, Koriesh A, Babi MA, Mayberry W, Goldstein ED, Pervez M, Nouh A. Testosterone supplementation and stroke in young adults: a review of the literature. Front Neurol. 2024;15:1422931. https:\/\/doi.org\/10.3389\/fneur.2024.1422931.","journal-title":"Front Neurol"},{"key":"1426_CR17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11883-006-0046-4","volume":"8","author":"S Guthikonda","year":"2006","unstructured":"Guthikonda S, Haynes WG. Homocysteine: role and implications in atherosclerosis. Curr Atheroscler Rep. 2006;8:100\u20136. https:\/\/doi.org\/10.1007\/s11883-006-0046-4.","journal-title":"Curr Atheroscler Rep"},{"key":"1426_CR18","doi-asserted-by":"publisher","first-page":"10875","DOI":"10.1080\/21655979.2022.2066608","volume":"13","author":"T Li","year":"2022","unstructured":"Li T, Dong G, Kang Y, Zhang M, Sheng X, Wang Z, Liu Y, Kong N, Sun H. Increased homocysteine regulated by androgen activates autophagy by suppressing the mammalian target of rapamycin pathway in the granulosa cells of polycystic ovary syndrome mice. Bioengineered. 2022;13:10875\u201388. https:\/\/doi.org\/10.1080\/21655979.2022.2066608.","journal-title":"Bioengineered"},{"key":"1426_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.rbmo.2018.05.008","volume":"37","author":"D Li","year":"2018","unstructured":"Li D, Liu H-X, Fang Y-Y, Huo J-N, Wu Q-J, Wang T-R, Zhou Y-M, Wang X-X, Ma X-X. Hyperhomocysteinemia in polycystic ovary syndrome: decreased betaine-homocysteine methyltransferase and cystathionine \u03b2-synthase-mediated homocysteine metabolism. Reprod Biomed Online. 2018;37:234\u201341. https:\/\/doi.org\/10.1016\/j.rbmo.2018.05.008.","journal-title":"Reprod Biomed Online"},{"key":"1426_CR20","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1161\/STROKEAHA.121.038035","volume":"53","author":"R Molenberg","year":"2022","unstructured":"Molenberg R, Thio CHL, Aalbers MW, Uyttenboogaart M, ISGC Intracranial Aneurysm Working Group, Larsson SC, Bakker MK, Ruigrok YM, Snieder H, van Dijk JMC. Sex Hormones and Risk of Aneurysmal Subarachnoid Hemorrhage: A Mendelian Randomization Study. Stroke. 2022;53:2870\u20135. https:\/\/doi.org\/10.1161\/STROKEAHA.121.038035.","journal-title":"Stroke"},{"key":"1426_CR21","doi-asserted-by":"publisher","first-page":"111793","DOI":"10.1016\/j.mad.2023.111793","volume":"211","author":"C Vinciguerra","year":"2023","unstructured":"Vinciguerra C, Iacono S, Bevilacqua L, et al. Sex differences in neuromuscular disorders. Mech Ageing Dev. 2023;211:111793. https:\/\/doi.org\/10.1016\/j.mad.2023.111793.","journal-title":"Mech Ageing Dev"},{"key":"1426_CR22","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.yfrne.2011.06.003","volume":"32","author":"S Parodi","year":"2011","unstructured":"Parodi S, Pennuto M. Neurotoxic effects of androgens in spinal and bulbar muscular atrophy. Front Neuroendocrinol. 2011;32:416\u201325. https:\/\/doi.org\/10.1016\/j.yfrne.2011.06.003.","journal-title":"Front Neuroendocrinol"},{"key":"1426_CR23","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/s0896-6273(02)00875-9","volume":"35","author":"K-I Takeyama","year":"2002","unstructured":"Takeyama K-I, Ito S, Yamamoto A, Tanimoto H, Furutani T, Kanuka H, Miura M, Tabata T, Kato S. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron. 2002;35:855\u201364. https:\/\/doi.org\/10.1016\/s0896-6273(02)00875-9.","journal-title":"Neuron"},{"key":"1426_CR24","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/s0896-6273(02)00834-6","volume":"35","author":"M Katsuno","year":"2002","unstructured":"Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, Niwa H, Sang C, Kobayashi Y, Doyu M, Sobue G. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron. 2002;35:843\u201354. https:\/\/doi.org\/10.1016\/s0896-6273(02)00834-6.","journal-title":"Neuron"},{"key":"1426_CR25","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S1474-4422(10)70321-5","volume":"10","author":"LE Fern\u00e1ndez-Rhodes","year":"2011","unstructured":"Fern\u00e1ndez-Rhodes LE, Kokkinis AD, White MJ, et al. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol. 2011;10:140\u20137. https:\/\/doi.org\/10.1016\/S1474-4422(10)70321-5.","journal-title":"Lancet Neurol"},{"key":"1426_CR26","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1136\/jnnp-2017-316015","volume":"88","author":"A Hashizume","year":"2017","unstructured":"Hashizume A, Katsuno M, Suzuki K, Hirakawa A, Hijikata Y, Yamada S, Inagaki T, Banno H, Sobue G. Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy: natural history-controlled study. J Neurol Neurosurg Psychiatry. 2017;88:1026\u201332. https:\/\/doi.org\/10.1136\/jnnp-2017-316015.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1426_CR27","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00415-019-09251-x","volume":"266","author":"A Hashizume","year":"2019","unstructured":"Hashizume A, Katsuno M, Suzuki K, et al. Efficacy and safety of leuprorelin acetate for subjects with spinal and bulbar muscular atrophy: pooled analyses of two randomized-controlled trials. J Neurol. 2019;266:1211\u201321. https:\/\/doi.org\/10.1007\/s00415-019-09251-x.","journal-title":"J Neurol"},{"key":"1426_CR28","doi-asserted-by":"publisher","first-page":"808479","DOI":"10.3389\/fendo.2022.808479","volume":"13","author":"VM McLeod","year":"2022","unstructured":"McLeod VM, Chiam MDF, Perera ND, Lau CL, Boon WC, Turner BJ. Mapping Motor Neuron Vulnerability in the Neuraxis of Male SOD1G93A Mice Reveals Widespread Loss of Androgen Receptor Occurring Early in Spinal Motor Neurons. Front Endocrinol. 2022;13:808479. https:\/\/doi.org\/10.3389\/fendo.2022.808479.","journal-title":"Front Endocrinol"},{"key":"1426_CR29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1001\/archneur.1980.00500520027002","volume":"37","author":"LP Weiner","year":"1980","unstructured":"Weiner LP. Possible role of androgen receptors in amyotrophic lateral sclerosis. A hypothesis. Arch Neurol. 1980;37:129\u2013213. https:\/\/doi.org\/10.1001\/archneur.1980.00500520027002.","journal-title":"Arch Neurol"},{"key":"1426_CR30","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1111\/bph.14657","volume":"176","author":"VM McLeod","year":"2019","unstructured":"McLeod VM, Lau CL, Chiam MDF, Rupasinghe TW, Roessner U, Djouma E, Boon WC, Turner BJ. Androgen receptor antagonism accelerates disease onset in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Br J Pharmacol. 2019;176:2111\u201330. https:\/\/doi.org\/10.1111\/bph.14657.","journal-title":"Br J Pharmacol"},{"key":"1426_CR31","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/j.neurobiolaging.2014.02.004","volume":"35","author":"T Aggarwal","year":"2014","unstructured":"Aggarwal T, Polanco MJ, Scaramuzzino C, et al. Androgens affect muscle, motor neuron, and survival in a mouse model of SOD1-related amyotrophic lateral sclerosis. Neurobiol Aging. 2014;35:1929\u201338. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2014.02.004.","journal-title":"Neurobiol Aging"},{"key":"1426_CR32","doi-asserted-by":"publisher","first-page":"9255","DOI":"10.1038\/s41598-021-88415-0","volume":"11","author":"D Tomas","year":"2021","unstructured":"Tomas D, McLeod VM, Chiam MDF, Wanniarachchillage N, Boon WC. Turner BJ (2021) Dissociation of disease onset, progression and sex differences from androgen receptor levels in a mouse model of amyotrophic lateral sclerosis. Sci Rep. 2021;11:9255. https:\/\/doi.org\/10.1038\/s41598-021-88415-0.","journal-title":"Sci Rep"},{"key":"1426_CR33","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1093\/hmg\/ddx150","volume":"26","author":"S Ponnusamy","year":"2017","unstructured":"Ponnusamy S, Sullivan RD, You D, et al. Androgen receptor agonists increase lean mass, improve cardiopulmonary functions and extend survival in preclinical models of Duchenne muscular dystrophy. Hum Mol Genet. 2017;26:2526\u201340. https:\/\/doi.org\/10.1093\/hmg\/ddx150.","journal-title":"Hum Mol Genet"},{"key":"1426_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1530\/EJE-20-0709","volume":"184","author":"CL Wood","year":"2021","unstructured":"Wood CL, Hollingsworth KG, Hughes E, Punniyakodi S, Muni-Lofra R, Mayhew A, Mitchell RT, Guglieri M, Cheetham TD, Straub V. Pubertal induction in adolescents with DMD is associated with high satisfaction, gonadotropin release and increased muscle contractile surface area. Eur J Endocrinol. 2021;184:67\u201379. https:\/\/doi.org\/10.1530\/EJE-20-0709.","journal-title":"Eur J Endocrinol"},{"key":"1426_CR35","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1093\/hmg\/ddaf028","volume":"34","author":"K Nakamura","year":"2025","unstructured":"Nakamura K, Kanou M, Fujii W, Kouzaki K, Jimbo T, Yamanouchi K, Nakazato K, Ueda H, Hirata J, Yamana K. New selective androgen receptor modulator TEI-SARM2 improves muscle function in a Duchenne muscular dystrophy rat model. Hum Mol Genet. 2025;34:852\u201363. https:\/\/doi.org\/10.1093\/hmg\/ddaf028.","journal-title":"Hum Mol Genet"},{"key":"1426_CR36","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1212\/wnl.56.8.1075","volume":"56","author":"GM Fenichel","year":"2001","unstructured":"Fenichel GM, Griggs RC, Kissel J, et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology. 2001;56:1075\u20139. https:\/\/doi.org\/10.1212\/wnl.56.8.1075.","journal-title":"Neurology"},{"key":"1426_CR37","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1212\/WNL.58.7.1081","volume":"58","author":"SB Rutkove","year":"2002","unstructured":"Rutkove SB, Parker RA, Nardin RA, Connolly CE, Felice KJ, Raynor EM. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology. 2002;58:1081\u20137. https:\/\/doi.org\/10.1212\/WNL.58.7.1081.","journal-title":"Neurology"},{"key":"1426_CR38","doi-asserted-by":"publisher","first-page":"e1416","DOI":"10.1002\/cti2.1416","volume":"11","author":"JD Coudert","year":"2022","unstructured":"Coudert JD, Slater N, Sooda A, et al. Immunoregulatory effects of testosterone supplementation combined with exercise training in men with Inclusion Body Myositis: a double-blind, placebo-controlled, cross-over trial. Clin Transl Immunol. 2022;11:e1416. https:\/\/doi.org\/10.1002\/cti2.1416.","journal-title":"Clin Transl Immunol"},{"key":"1426_CR39","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1210\/jcem-60-3-611","volume":"60","author":"JN Carter","year":"1985","unstructured":"Carter JN, Steinbeck KS. Reduced adrenal androgens in patients with myotonic dystrophy. J Clin Endocrinol Metab. 1985;60:611\u20134. https:\/\/doi.org\/10.1210\/jcem-60-3-611.","journal-title":"J Clin Endocrinol Metab"},{"key":"1426_CR40","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/archneur.1985.04060080063017","volume":"42","author":"RC Griggs","year":"1985","unstructured":"Griggs RC, Kingston W, Herr BE, Forbes G, Moxley RT. Lack of relationship of hypogonadism to muscle wasting in myotonic dystrophy. Arch Neurol. 1985;42:881\u20135. https:\/\/doi.org\/10.1001\/archneur.1985.04060080063017.","journal-title":"Arch Neurol"},{"key":"1426_CR41","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1212\/wnl.39.2.219","volume":"39","author":"RC Griggs","year":"1989","unstructured":"Griggs RC, Pandya S, Florence JM, Brooke MH, Kingston W, Miller JP, et al. Randomized controlled trial of testosterone in myotonic dystrophy. Neurology. 1989;39:219\u201322. https:\/\/doi.org\/10.1212\/wnl.39.2.219.","journal-title":"Neurology"},{"key":"1426_CR42","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1210\/en.2018-00660","volume":"159","author":"Y Lei","year":"2018","unstructured":"Lei Y, Renyuan Z. Effects of Androgens on the Amyloid-\u03b2 Protein in Alzheimer\u2019s Disease. Endocrinology. 2018;159:3885\u201394. https:\/\/doi.org\/10.1210\/en.2018-00660.","journal-title":"Endocrinology"},{"key":"1426_CR43","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1002\/alz.13013","volume":"19","author":"CDJ Kusters","year":"2023","unstructured":"Kusters CDJ, Paul KC, Romero T, Sinsheimer JS, Ritz BR. Among men, androgens are associated with a decrease in Alzheimer\u2019s disease risk. Alzheimer\u2019s & Dementia. 2023;19:3826\u201334. https:\/\/doi.org\/10.1002\/alz.13013.","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"1426_CR44","doi-asserted-by":"publisher","first-page":"bvaa120","DOI":"10.1210\/jendso\/bvaa120","volume":"4","author":"VE Bianchi","year":"2020","unstructured":"Bianchi VE, Rizzi L, Bresciani E, Omeljaniuk RJ, Torsello A. Androgen Therapy in Neurodegenerative Diseases. J Endocr Soc. 2020;4:bvaa120. https:\/\/doi.org\/10.1210\/jendso\/bvaa120.","journal-title":"J Endocr Soc"},{"key":"1426_CR45","doi-asserted-by":"publisher","first-page":"13384","DOI":"10.1523\/JNEUROSCI.2514-06.2006","volume":"26","author":"ER Rosario","year":"2006","unstructured":"Rosario ER, Carroll JC, Oddo S, LaFerla FM, Pike CJ. Androgens Regulate the Development of Neuropathology in a Triple Transgenic Mouse Model of Alzheimer\u2019s Disease. J Neurosci. 2006;26:13384\u20139. https:\/\/doi.org\/10.1523\/JNEUROSCI.2514-06.2006.","journal-title":"J Neurosci"},{"key":"1426_CR46","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.14336\/AD.2019.1026","volume":"11","author":"CH Poon","year":"2020","unstructured":"Poon CH, Wang Y, Fung M-L, Zhang C, Lim LW. Rodent Models of Amyloid-Beta Feature of Alzheimer\u2019s Disease: Development and Potential Treatment Implications. Aging Dis. 2020;11:1235\u201359. https:\/\/doi.org\/10.14336\/AD.2019.1026.","journal-title":"Aging Dis"},{"key":"1426_CR47","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/gerona\/59.1.m75","volume":"59","author":"AM Kenny","year":"2024","unstructured":"Kenny AM, Fabregas G, Song C, Biskup B, Bellantonio S. Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss. J Gerontol A Biol Sci Med Sci. 2024;59:75\u20138. https:\/\/doi.org\/10.1093\/gerona\/59.1.m75.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1426_CR48","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jama.2016.21044","volume":"317","author":"SM Resnick","year":"2017","unstructured":"Resnick SM, Matsumoto AM, Stephens-Shields AJ, et al. Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment. JAMA. 2017;317:717\u201327. https:\/\/doi.org\/10.1001\/jama.2016.21044.","journal-title":"JAMA"},{"key":"1426_CR49","doi-asserted-by":"publisher","first-page":"1350318","DOI":"10.3389\/fendo.2024.1350318","volume":"15","author":"C Andy","year":"2024","unstructured":"Andy C, Nerattini M, Jett S, et al. Systematic review and meta-analysis of the effects of menopause hormone therapy on cognition. Front Endocrinol. 2024;15:1350318. https:\/\/doi.org\/10.3389\/fendo.2024.1350318.","journal-title":"Front Endocrinol"},{"key":"1426_CR50","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3389\/fnagi.2023.1158001","volume":"2","author":"A Giannini","year":"2021","unstructured":"Giannini A, Caretto M, Genazzani AR, Simoncini T. Neuroendocrine Changes during Menopausal Transition. Endocrines. 2021;2:405\u201316. https:\/\/doi.org\/10.3389\/fnagi.2023.1158001.","journal-title":"Endocrines"},{"key":"1426_CR51","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","volume":"403","author":"Y Ben-Shlomo","year":"2024","unstructured":"Ben-Shlomo Y, Darweesh S, Llibre-Guerra J, Marras C, San Luciano M, Tanner C. The epidemiology of Parkinson\u2019s disease. Lancet. 2024;403:283\u201392. https:\/\/doi.org\/10.1016\/S0140-6736(23)01419-8.","journal-title":"Lancet"},{"key":"1426_CR52","first-page":"165","volume":"75","author":"MS Okun","year":"2004","unstructured":"Okun MS, Crucian GP, Fischer L, Walter BL, Testa CM, Vitek JL, DeLong MR, Hanfelt J, Huang X. Testosterone deficiency in a Parkinson\u2019s disease clinic: results of a survey. J Neurol Neurosurg Psychiatry. 2004;75:165\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1426_CR53","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1001\/archneur.63.5.729","volume":"63","author":"MS Okun","year":"2006","unstructured":"Okun MS, Fernandez HH, Rodriguez RL, et al. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study. Arch Neurol. 2006;63:729\u201335. https:\/\/doi.org\/10.1001\/archneur.63.5.729.","journal-title":"Arch Neurol"},{"key":"1426_CR54","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/archneur.59.5.807","volume":"59","author":"MS Okun","year":"2002","unstructured":"Okun MS, McDonald WM, DeLong MR. Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity. Arch Neurol. 2002;59:807\u201381. https:\/\/doi.org\/10.1001\/archneur.59.5.807.","journal-title":"Arch Neurol"},{"key":"1426_CR55","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/mdc3.13308","volume":"8","author":"P Gonzalez-Latapi","year":"2021","unstructured":"Gonzalez-Latapi P, Sousa M, Lang AE. Movement Disorders Associated with Hypogonadism. Mov Disord Clin Pract. 2021;8:997\u20131011. https:\/\/doi.org\/10.1002\/mdc3.13308.","journal-title":"Mov Disord Clin Pract"},{"key":"1426_CR56","doi-asserted-by":"publisher","first-page":"578206","DOI":"10.1016\/j.jneuroim.2023.578206","volume":"384","author":"S Hosseinzadeh","year":"2023","unstructured":"Hosseinzadeh S, Afshari S, Molaei S, Rezaei N, Dadkhah M. The role of genetics and gender specific differences in neurodegenerative disorders: Insights from molecular and immune landscape. J Neuroimmunol. 2023;384:578206. https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578206.","journal-title":"J Neuroimmunol"},{"key":"1426_CR57","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/archneur.64.5.683","volume":"64","author":"NL Sicotte","year":"2007","unstructured":"Sicotte NL, Giesser BS, Tandon V, et al. Testosterone treatment in multiple sclerosis: a pilot study. Arch Neurol. 2007;64:683\u20138. https:\/\/doi.org\/10.1001\/archneur.64.5.683.","journal-title":"Arch Neurol"},{"key":"1426_CR58","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1742-2094-5-32","volume":"5","author":"SM Gold","year":"2008","unstructured":"Gold SM, Chalifoux S, Giesser BS, Voskuhl RR. Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone. J Neuroinflammation. 2008;5:32. https:\/\/doi.org\/10.1186\/1742-2094-5-32.","journal-title":"J Neuroinflammation"},{"key":"1426_CR59","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/brain\/aws284","volume":"136","author":"R Hussain","year":"2013","unstructured":"Hussain R, Ghoumari AM, Bielecki B, et al. The neural androgen receptor: a therapeutic target for myelin repair in chronic demyelination. Brain. 2013;136:132\u201346. https:\/\/doi.org\/10.1093\/brain\/aws284.","journal-title":"Brain"},{"key":"1426_CR60","doi-asserted-by":"publisher","first-page":"14829","DOI":"10.1073\/pnas.1614826113","volume":"113","author":"B Bielecki","year":"2016","unstructured":"Bielecki B, Mattern C, Ghoumari AM, et al. Unexpected central role of the androgen receptor in the spontaneous regeneration of myelin. Proc Natl Acad Sci. 2016;113:14829\u201334. https:\/\/doi.org\/10.1073\/pnas.1614826113.","journal-title":"Proc Natl Acad Sci"},{"key":"1426_CR61","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.nicl.2014.03.001","volume":"4","author":"F Kurth","year":"2014","unstructured":"Kurth F, Luders E, Sicotte NL, Gaser C, Giesser BS, Swerdloff RS, Montag MJ, Voskuhl RR, Mackenzie-Graham A. Neuroprotective effects of testosterone treatment in men with multiple sclerosis. NeuroImage: Clin. 2014;4:454. https:\/\/doi.org\/10.1016\/j.nicl.2014.03.001.","journal-title":"NeuroImage: Clin"},{"key":"1426_CR62","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1186\/s13063-020-04517-6","volume":"21","author":"K Metzger-Peter","year":"2020","unstructured":"Metzger-Peter K, Kremer LD, Edan G, et al. The TOTEM RRMS (Testosterone Treatment on neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis) trial: study protocol for a randomized, double-blind, placebo-controlled trial. Trials. 2020;21:591. https:\/\/doi.org\/10.1186\/s13063-020-04517-6.","journal-title":"Trials"},{"key":"1426_CR63","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1212\/wnl.50.3.782","volume":"50","author":"AG Herzog","year":"1998","unstructured":"Herzog AG, Klein P, Jacobs AR. Testosterone versus testosterone and testolactone in treating reproductive and sexual dysfunction in men with epilepsy and hypogonadism. Neurology. 1998;50:782\u20134. https:\/\/doi.org\/10.1212\/wnl.50.3.782.","journal-title":"Neurology"},{"key":"1426_CR64","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/j.1528-1157.1997.tb01197.x","volume":"38","author":"AG Herzog","year":"1997","unstructured":"Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia. 1997;38:1082\u20138. https:\/\/doi.org\/10.1111\/j.1528-1157.1997.tb01197.x.","journal-title":"Epilepsia"},{"key":"1426_CR65","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.yebeh.2003.12.001","volume":"5","author":"C Harden","year":"2004","unstructured":"Harden C, MacLusky NJ. Aromatase inhibition, testosterone, and seizures. Epilepsy Behav. 2004;5:260\u20133. https:\/\/doi.org\/10.1016\/j.yebeh.2003.12.001.","journal-title":"Epilepsy Behav"},{"key":"1426_CR66","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.yebeh.2005.08.028","volume":"7","author":"GL Morris 3rd","year":"2005","unstructured":"Morris GL 3rd, Vanderkolk C. Human sexuality, sex hormones, and epilepsy. Epilepsy Behav. 2005;7:22\u20138. https:\/\/doi.org\/10.1016\/j.yebeh.2005.08.028.","journal-title":"Epilepsy Behav"},{"key":"1426_CR67","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.seizure.2015.02.012","volume":"28","author":"E Taub\u00f8ll","year":"2015","unstructured":"Taub\u00f8ll E, Sveberg L, Svalheim S. Interactions between hormones and epilepsy. Seizure. 2015;28:3\u201311. https:\/\/doi.org\/10.1016\/j.seizure.2015.02.012.","journal-title":"Seizure"},{"key":"1426_CR68","doi-asserted-by":"publisher","first-page":"8079","DOI":"10.4081\/ni.2019.8079","volume":"11","author":"LBE Shields","year":"2019","unstructured":"Shields LBE, Seifert T, Shelton BJ, Plato BM. Testosterone levels in men with chronic migraine. Neurol Int. 2019;11:8079. https:\/\/doi.org\/10.4081\/ni.2019.8079.","journal-title":"Neurol Int"},{"key":"1426_CR69","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s10194-021-01334-3","volume":"22","author":"IE Verhagen","year":"2021","unstructured":"Verhagen IE, Brandt RB, Kruitbosch CMA, MaassenVanDenBrink A, Fronczek R, Terwindt GM. Clinical symptoms of androgen deficiency in men with migraine or cluster headache: a cross-sectional cohort study. J Headache Pain. 2021;22:125. https:\/\/doi.org\/10.1186\/s10194-021-01334-3.","journal-title":"J Headache Pain"},{"key":"1426_CR70","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.maturitas.2012.01.006","volume":"71","author":"R Glaser","year":"2012","unstructured":"Glaser R, Dimitrakakis C, Trimble N, Martin V. Testosterone pellet implants and migraine headaches: a pilot study. Maturitas. 2012;71:385\u20138. https:\/\/doi.org\/10.1016\/j.maturitas.2012.01.006.","journal-title":"Maturitas"},{"key":"1426_CR71","doi-asserted-by":"publisher","first-page":"1117842","DOI":"10.3389\/fpain.2023.1117842","volume":"4","author":"CI Martinez","year":"2023","unstructured":"Martinez CI, Liktor-Busa E, Largent-Milnes TM. Molecular mechanisms of hormones implicated in migraine and the translational implication for transgender patients. Front Pain Res. 2023;4:1117842. https:\/\/doi.org\/10.3389\/fpain.2023.1117842.","journal-title":"Front Pain Res"},{"key":"1426_CR72","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/ana.26906","volume":"95","author":"AS Petersen","year":"2024","unstructured":"Petersen AS, Kristensen DM, Westgate CSJ, et al. Compensated Hypogonadism Identified in Males with Cluster Headache: A Prospective Case-Controlled Study. Ann Neurol. 2024;95:1149\u201361. https:\/\/doi.org\/10.1002\/ana.26906.","journal-title":"Ann Neurol"},{"key":"1426_CR73","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/j.1526-4610.2006.00436.x","volume":"46","author":"MJ Stillman","year":"2006","unstructured":"Stillman MJ. Testosterone replacement therapy for treatment refractory cluster headache. Headache. 2006;46:925\u201333. https:\/\/doi.org\/10.1111\/j.1526-4610.2006.00436.x.","journal-title":"Headache"},{"key":"1426_CR74","unstructured":"Research and Markets. Testosterone Replacement Therapy Market Forecast Report 2025\u20132033, with Key Player Profiles for AbbVie, Clarus Therapeutics, Ferring Pharmaceuticals, Lupin, Pfizer, Teva Pharmaceuticals and More. GlobeNewswire. [Internet]. Dublin: Research and Markets; 2025 Feb 10 [cited 2025 May 5]. Available from: https:\/\/www.globenewswire.com\/news-release\/2025\/02\/10\/3023711\/28124\/en\/Testosterone-Replacement-Therapy-Market-Forecast-Report-2025-2033-with-Key-Player-Profiles-for-AbbVie-Clarus-Therapeutics-Ferring-Pharmaceuticals-Lupin-Pfizer-Teva-Pharmaceuticals-.html"},{"key":"1426_CR75","unstructured":"U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. FDA. [Internet]. Silver Spring (MD): FDA; 2015 Mar 3 [cited 2025 May 5]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-cautions-about-using-testosterone-products-low-testosterone-due"},{"key":"1426_CR76","unstructured":"Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. Am Coll Cardiol. [Internet]. 2023 Jun 20 [cited 2025 Apr 25]. Available from: https:\/\/www.acc.org\/latest-in-cardiology\/journal-scans\/2023\/06\/20\/14\/42\/cardiovascular-safety-of-testosterone"},{"key":"1426_CR77","unstructured":"Rubenfire M. Testosterone and Cardiovascular Disease. Am Coll Cardiol. [Internet]. 2016 Feb 1 [cited 2025 Apr 25]. Available from: https:\/\/www.acc.org\/Latest-in-Cardiology\/ten-points-to-remember\/2016\/02\/01\/13\/31\/Testosterone-and-Cardiovascular-Disease"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-025-01426-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-025-01426-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-025-01426-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T08:57:45Z","timestamp":1748941065000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-025-01426-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1426"],"URL":"https:\/\/doi.org\/10.1007\/s11910-025-01426-6","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"9 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"None relevant. Dr. Nouh discloses holding stock shares of Open Water.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"39"}}